XML 46 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Oct. 02, 2020
Mar. 01, 2020
Dec. 06, 2018
Nov. 28, 2018
Dec. 22, 2017
Sep. 27, 2017
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Jan. 09, 2020
Dec. 31, 2019
Feb. 28, 2002
Commitments (Textual)                          
Royalty percentage                         2.50%
Description of royalty         The Company entered into an agreement (the “Feinstein Agreement”) with The Feinstein Institute for Medical Research (the “Feinstein Institute”), a not-for-profit corporation with 50 research labs and 2,500 clinical research studies. Pursuant to the Feinstein Agreement, the Company acquired an exclusive license relating to treatment of fatty liver diseases in humans for which Choline may be an effective therapeutic. In consideration for the rights and license granted, the Feinstein Institute would receive a royalty of one percent (1%) of the first one hundred million dollars ($100,000,000) of net sales of IV Choline Chloride and a royalty of one and one-half percent (1.5%) of all net sales thereafter. In addition, the Company would pay the Feinstein Institute twelve and one-half percent (12.5%) of net proceeds resulting from agreements entered within 2 years from the Effective Date, and seven and one-half percent (7.5%) of net proceeds resulting from agreements entered into thereafter. Pursuant to the Feinstein Agreement additional payments would be due to the Feinstein Institute for license maintenance payments and for meeting milestone events. On January 9, 2020, the Company’s raising of over $5,000,000 triggered a financing milestone obligation and accordingly the Feinstein Institute was paid $100,000. Pursuant to the Feinstein Agreement, upon the achievement of certain future new drug application milestones, the Company would be obligated to remit an aggregate of $275,000.                
Lease term             93 months   93 months   8 years    
Lease Agreements [Member]                          
Commitments (Textual)                          
Description of agreements   On March 1, 2020, the Company entered into new month-to-month lease agreements for three additional office spaces at monthly rents of $4,890, $1,270 and $7,200. On June 30, 2020, the Company terminated the lease agreements for these office spaces and entered into a new three-month agreement for a smaller office space at a monthly rent of $810.                      
Monthly rent                 $ 810        
Executive Employment Agreements [Member]                          
Commitments (Textual)                          
Description of agreements                 In connection with the consummation of the Merger, Jesse Shefferman, the Company’s Chief Executive Officer, had his base salary increased from $365,000 to $510,000 and Jacqueline Zummo, the Company’s Head of Operations and Medical Affairs, had her base salary increased from $305,000 to $325,000. The Company also entered into an employment agreement with Blaine Davis to become the Company’s Chief Financial Officer on January 31, 2020, effective as of February 11, 2020, for a base salary of $385,000, and with Julio Casoy to become the Company’s Chief Medical Officer, on February 6, 2020, for a base salary of $400,000.        
Research and development expenses                 $ 210,813        
General and administrative expenses                 259,688        
Executive Employment Agreements [Member] | Mr. Shefferman [Member]                          
Commitments (Textual)                          
Bonus payments                 259,688        
Executive Employment Agreements [Member] | Dr. Zummo [Member]                          
Commitments (Textual)                          
Bonus payments                 95,313        
Executive Employment Agreements [Member] | Dr. Casoy [Member]                          
Commitments (Textual)                          
Bonus payments                 115,500        
Temporary Employment Agreement [Member]                          
Commitments (Textual)                          
Annual base salary     $ 90,000                    
Compensation obligation                     $ 462,500    
Clinical Services Agreements [Member]                          
Commitments (Textual)                          
Description of license agreement           The Company entered into a license agreement (the “Choline License Agreement”) with Alan L. Buchman (“Dr. Buchman”). Pursuant to the Choline License Agreement, the Company received from Dr. Buchman the license rights in and to the “Licensed Orphan Designations”, the “Licensed IND”, “Existing Study Data” and the “Licensed Know-How” for one or more of the licensed indications. In consideration for the rights and licenses granted, Dr. Buchman received a payment of $50,000 on October 2, 2017, and license payments of $50,000 and $50,000 on December 12, 2018 and January 8, 2019, respectively, upon the Company meeting the criteria for certain meetings to be held with the Federal Drug Administration (the “FDA”). Pursuant to the Choline License Agreement, effective October 2017, the Company incurred a fixed obligation to Dr. Buchman of $400,000 (the “Choline License Fee”). Upon the Company receiving $5,000,000 in cumulative funding (as defined), Dr. Buchman would be entitled to receive payment of the Choline License Fee as a lump sum if the funds are received by April 15, 2019 and the Choline License Fee shall be increased to a one-time payment of $600,000 if the funds are received by October 15, 2019.              
Research and development expenses             $ 0 $ 200,000 0 $ 200,000      
Clinical Services Agreements [Member] | Dr. Buchman [Member]                          
Commitments (Textual)                          
Choline License Fee $ 50,000                        
Accrued expenses                       $ 550,000  
Feinstein Agreement [Member]                          
Commitments (Textual)                          
Research and development expenses             0 0 100,000 0      
Iowa Agreement [Member]                          
Commitments (Textual)                          
Description of agreements       The Company entered into a sponsored research and license agreement (the “Iowa Agreement”) with the University of Iowa. Pursuant to the Iowa Agreement, the University of Iowa, which is engaged in clinical research to improve the diagnosis and treatment of lymphangioma using a pharmaceutical product (Ok-432), would assist the Company in collecting case reports, forms, source data, and safety data available to the University of Iowa in support of the development of the Company’s proprietary Streptococcus Pyogenes investigational product, TARA-002. During the term of the services, the Company would pay the University of Iowa thirty thousand dollars ($30,000) per year to fund the project, plus additional amounts upon the realization of certain milestones. More specifically, upon forty-five (45) days of an approval of the TARA-002 by the FDA, the Company would pay up to $1,750,000 to the University of Iowa for meeting their milestones. Furthermore, the Company would pay the University of Iowa royalties of up to 1.75% for net sales ranging from $0 - $25,000,000, 2.25% for net sales ranging from $25,000,000+ to $50,000,000, and 2.50% for net sales of $50,000,000+. Pursuant to the Iowa Agreement, the University of Iowa would be entitled to additional payments for annual net sales payments as per the following milestones. For annual net sales of product up to $25,000,000; $62,500; for annual net sales of product of up to $50,000,000; $62,500; and for annual net sales of product of up to $100,000,000; $125,000.                  
Research and development expenses             7,500 7,500 15,000 15,000      
Chugai Pharmaceutical Agreement [Member]                          
Commitments (Textual)                          
Compensation obligation                       $ 500,000  
Research and development expenses             $ 0 $ 0 $ 0 $ 0